http://pharmaweblog.com/blog/2006/08/08/interim-analysis-part-1-role-of-the-data-monitoring-committee/ Pharmaceutical and biotech science and business Wed, 20 Aug 2008 11:02:56 +0000 http://wordpress.org/?v=2.0.2 http://pharmaweblog.com/blog/2006/08/08/interim-analysis-part-1-role-of-the-data-monitoring-committee/#comment-31 Wed, 22 Nov 2006 22:22:59 +0000 http://pharmaweblog.com/blog/2006/08/08/interim-analysis-part-1-role-of-the-data-monitoring-committee/#comment-31 [...] The actions to stop the ADAPT trial are clearly antithetical to widely accepted prinicples for conducting interim safety analyses, as I have described in a previous blog post and recently published white paper.  It’s shocking that the U.S.’s leading health-research authority would be responsible for such blatant scientific misconduct.  It’s the type of action that should result in a GAO investigation and in the loss of job for those found to be chiefly responsible. Share with the world: These icons link to social bookmarking sites where readers can share and discover new web pages. [...] […] The actions to stop the ADAPT trial are clearly antithetical to widely accepted prinicples for conducting interim safety analyses, as I have described in a previous blog post and recently published white paper.  It’s shocking that the U.S.’s leading health-research authority would be responsible for such blatant scientific misconduct.  It’s the type of action that should result in a GAO investigation and in the loss of job for those found to be chiefly responsible. Share with the world: These icons link to social bookmarking sites where readers can share and discover new web pages. […]

]]>